Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
作者信息
Cuneo Antonio, Rigolin Gian Matteo, Coscia Marta, Quaresmini Giulia, Scarfò Lydia, Mauro Francesca Romana, Motta Marina, Quaglia Francesca Maria, Trentin Livio, Ferrario Andrea, Laurenti Luca, Reda Gianluigi, Ferrari Angela, Pietrasanta Daniela, Sportoletti Paolo, Re Francesca, De Paoli Lorenzo, Foglietta Myriam, Giordano Annamaria, Marchetti Monia, Farina Lucia, Del Poeta Giovanni, Varettoni Marzia, Chiurazzi Federico, Marasca Roberto, Malerba Lara, Ibatici Adalberto, Tisi Maria Chiara, Stefoni Vittorio, Leone Monica, Baratè Claudia, Olivieri Jacopo, Murru Roberta, Gentile Massimo, Sanna Alessandro, Gozzetti Alessandro, Gattei Valter, Gottardi Daniela, Derenzini Enrico, Levato Luciano, Orsucci Lorella, Penna Giuseppa, Chiarenza Annalisa, Foà Robin
机构信息
Hematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Division of Hematology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.
出版信息
Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.
Abstract
摘要
相似文献
1
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.意大利在新冠疫情一年期间及疫苗接种计划启动时慢性淋巴细胞白血病的管理。一份坎皮斯慢性淋巴细胞白血病报告。
Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.
2
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report.意大利在新冠疫情期间慢性淋巴细胞白血病的管理：校园慢性淋巴细胞白血病报告
Blood. 2020 Aug 6;136(6):763-766. doi: 10.1182/blood.2020006854.
3
COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.2019冠状病毒病疫苗接种：慢性淋巴细胞白血病患者疫苗接种失败风险评估
Hematol Oncol. 2021 Dec;39(5):712-714. doi: 10.1002/hon.2916. Epub 2021 Aug 30.
4
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.慢性淋巴细胞白血病患者的COVID-19：生存结果改善及管理策略更新
Blood. 2021 Nov 4;138(18):1768-1773. doi: 10.1182/blood.2021011841.
5
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.慢性淋巴细胞白血病患者的新冠病毒感染：连续患者 13 个月期间的临床结局和 B 细胞与 T 细胞免疫。
Leukemia. 2022 Feb;36(2):476-481. doi: 10.1038/s41375-021-01424-w. Epub 2021 Sep 25.
6
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.COVID-19 严重程度和死亡率在 CLL 患者中的研究：国际 ERIC 和 Campus CLL 研究的更新。
Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1.
7
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.接受针对新冠病毒病全剂量疫苗接种的B细胞恶性肿瘤患者血清阳性率低且中和率未达最佳水平。
Br J Haematol. 2021 Dec;195(5):706-709. doi: 10.1111/bjh.17836. Epub 2021 Sep 21.
8
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL.慢性淋巴细胞白血病（CLL）治疗期间的新冠病毒疾病（COVID-19）疫苗接种与COVID-19死亡的关系
Blood Adv. 2024 Oct 22;8(20):5262-5265. doi: 10.1182/bloodadvances.2024014121.
9
Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.慢性淋巴细胞白血病患者的免疫功能障碍及 COVID-19 大流行期间的挑战
Acta Haematol. 2021;144(5):508-518. doi: 10.1159/000514071. Epub 2021 Feb 25.
10
COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia.COVID-19 合并副流感病毒感染的慢性淋巴细胞白血病患者。
Eur J Haematol. 2020 Oct;105(4):508-511. doi: 10.1111/ejh.13475. Epub 2020 Jul 10.
引用本文的文献
1
Management of infections for patient treated with ibrutinib in clinical practice.临床实践中接受依鲁替尼治疗患者的感染管理
Front Oncol. 2024 Sep 10;14:1428464. doi: 10.3389/fonc.2024.1428464. eCollection 2024.
2
Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项系统评价和荟萃分析
Rev Assoc Med Bras (1992). 2024 Aug 16;70(8):e20240322. doi: 10.1590/1806-9282.20240322. eCollection 2024.
3
Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany.真实世界中 CLL 的诊断和治疗方法：来自托斯卡纳专家小组的 2022 年更新。
Clin Exp Med. 2023 Dec;23(8):4251-4264. doi: 10.1007/s10238-023-01244-5. Epub 2023 Nov 18.
4
COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?慢性淋巴细胞白血病患者中的新冠病毒肺炎：我们了解到了什么？
Acta Haematol. 2024;147(1):60-72. doi: 10.1159/000534540. Epub 2023 Oct 11.
5
COVID-19 in Adult Patients with Hematological Malignancies-Lessons Learned after Three Years of Pandemic.血液系统恶性肿瘤成年患者中的COVID-19——大流行三年后的经验教训
Biology (Basel). 2023 Apr 3;12(4):545. doi: 10.3390/biology12040545.
6
Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.慢性淋巴细胞白血病患者接种第四剂 BNT162b2 mRNA COVID-19 疫苗后的细胞和体液反应。
Eur J Haematol. 2023 Jan;110(1):99-108. doi: 10.1111/ejh.13878. Epub 2022 Oct 23.
7
COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report.大流行15个月期间急性淋巴细胞白血病患者的COVID-19感染情况。一份校园急性淋巴细胞白血病研究报告。
Haematologica. 2022 Aug 1;107(8):1955-1959. doi: 10.3324/haematol.2021.280289.
8
Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.关于慢性淋巴细胞白血病中 SARS-CoV-2 疫苗接种的当前观点。
Hematol Oncol. 2022 Aug;40(3):313-319. doi: 10.1002/hon.2990. Epub 2022 Mar 23.
本文引用的文献
1
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.2019冠状病毒病疫苗对慢性淋巴细胞白血病患者的疗效
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
2
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
3
A Community-Based Model to the COVID-19 Humanitarian Crisis.基于社区的应对 COVID-19 人道主义危机模式。
Front Cell Infect Microbiol. 2021 Mar 15;11:639579. doi: 10.3389/fcimb.2021.639579. eCollection 2021.
4
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.癌症患者参与肿瘤临床试验的 COVID-19 疫苗接种指南。
Nat Rev Clin Oncol. 2021 May;18(5):313-319. doi: 10.1038/s41571-021-00487-z. Epub 2021 Mar 15.
5
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic.在新型冠状病毒肺炎大流行期间，我们如何管理慢性淋巴细胞白血病患者。
Hemasphere. 2020 Jul 30;4(4):e432. doi: 10.1097/HS9.0000000000000432. eCollection 2020 Aug.
6
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.慢性淋巴细胞白血病患者的 COVID-19 严重程度和死亡率：ERIC、欧洲慢性淋巴细胞白血病研究倡议和 CLL 校园的联合研究。
Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.
7
COVID-19 among fit patients with CLL treated with venetoclax-based combinations.接受基于维奈克拉的联合治疗的健康慢性淋巴细胞白血病患者中的 COVID-19 情况。
Leukemia. 2020 Aug;34(8):2225-2229. doi: 10.1038/s41375-020-0941-7. Epub 2020 Jun 29.
8
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report.意大利在新冠疫情期间慢性淋巴细胞白血病的管理：校园慢性淋巴细胞白血病报告
Blood. 2020 Aug 6;136(6):763-766. doi: 10.1182/blood.2020006854.
9
Severe Covid-19.重症新型冠状病毒肺炎
N Engl J Med. 2020 Dec 17;383(25):2451-2460. doi: 10.1056/NEJMcp2009575. Epub 2020 May 15.
Zotero 插件